Skip to main content
. 2012 Oct 31;12(1):215–227. doi: 10.1074/mcp.M112.023176

Fig. 3.

Fig. 3.

Validation of the lower abundant candidate MFM biomarker myomesin-1 and -2 by immunofluorescence analysis. Immunofluorescence analyses were performed on frozen serial sections of skeletal muscle biopsies from filaminopathy patients. Corresponding to the results of the proteome study, abnormal fibers with an increased immunoreactivity for myotilin (C) revealed a decreased immunoreactivity for myomesin-1 (A) and myomesin-2 (B).